National Bank of Canada’s Celyad Oncology SA American Depositary Shares CYAD Stock Holding History

National Bank of Canada’s Portfolio CYAD Stock Details CYAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-3,400	Closed	-$3.09K	–	2874
2023 Q1	$3.09K	Hold	3,400	–	–	﹤0.01%	2371
2022 Q4	$1.67K	Hold	3,400	–	–	﹤0.01%	2524
2022 Q3	$5K	Hold	3,400	–	–	﹤0.01%	2361
2022 Q2	$5K	Hold	3,400	–	–	﹤0.01%	2442
2022 Q1	$8K	Hold	3,400	–	–	﹤0.01%	2452
2021 Q4	$12K	Buy	+3,400	New	+$14.3K	﹤0.01%	2313

Other funds holding CYAD

BBA

Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return

National Bank of Canada's CYAD Position: Q2 2023 in Review

National Bank of Canada sold out of Celyad Oncology SA American Depositary Shares (CYAD) in Q2 2023, closing a stake of 3,400 shares — an estimated $3.09K sold.

National Bank of Canada first reported a position in CYAD in Q4 2021 and held it in 6 quarters. The position peaked at $12K in Q4 2021. 2 funds tracked by Wall St. Rank hold CYAD as of Q2 2023.

National Bank of Canada reported no remaining Celyad Oncology SA American Depositary Shares position as of Q2 2023 after selling out during the quarter.
National Bank of Canada sold 3,400 Celyad Oncology SA American Depositary Shares shares in Q2 2023, an estimated $3.09K.
National Bank of Canada first reported a position in Celyad Oncology SA American Depositary Shares in Q4 2021 and held it in 6 quarters.
National Bank of Canada's Celyad Oncology SA American Depositary Shares position peaked at $12K in Q4 2021.
2 funds tracked by Wall St. Rank held Celyad Oncology SA American Depositary Shares as of Q2 2023.

Based on National Bank of Canada's 13F filing for Q2 2023, filed 26 Jul 2023.